SCN5A and long QT syndrome 3: However, some SCN5A mutations impair mexiletine effects and the drug may favor Na channel trafficking to the membrane, thus raising concerns about the indiscriminate use of sodium channel blockers in LQT3 without careful individual testing (Ruan et al., 2007, 2010).